
Harrow, Inc. (NASDAQ:HROW – Free Report) – Equities researchers at HC Wainwright lifted their Q4 2026 earnings estimates for Harrow in a note issued to investors on Wednesday, November 11th. HC Wainwright analyst Y. Chen now anticipates that the company will earn $0.65 per share for the quarter, up from their previous estimate of $0.61. The consensus estimate for Harrow’s current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Harrow’s Q3 2027 earnings at $0.32 EPS.
Harrow (NASDAQ:HROW – Get Free Report) last released its quarterly earnings results on Monday, November 9th. The company reported $0.25 EPS for the quarter, topping analysts’ consensus estimates of $0.19 by $0.06. Harrow had a negative net margin of 9.39% and a negative return on equity of 69.81%. The firm had revenue of $99.30 million during the quarter, compared to analysts’ expectations of $98.59 million.
Check Out Our Latest Stock Analysis on Harrow
Harrow Stock Performance
HROW opened at $30.12 on Thursday. The stock’s 50 day moving average price is $30.77 and its 200-day moving average price is $37.52. Harrow has a one year low of $25.76 and a one year high of $54.85. The company has a quick ratio of 2.08, a current ratio of 2.29 and a debt-to-equity ratio of 10.15.
Institutional Trading of Harrow
Institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. bought a new position in Harrow in the second quarter worth approximately $116,373,000. Luxor Capital Group LP increased its holdings in Harrow by 22.0% during the 1st quarter. Luxor Capital Group LP now owns 1,119,400 shares of the company’s stock worth $39,470,000 after purchasing an additional 201,859 shares during the period. Bamco Inc. NY bought a new stake in Harrow during the 2nd quarter valued at $34,373,000. Jupiter Topco LLC bought a new stake in Harrow during the 2nd quarter valued at $24,596,000. Finally, Dimensional Fund Advisors LP raised its position in Harrow by 56.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 579,520 shares of the company’s stock valued at $20,428,000 after purchasing an additional 208,972 shares in the last quarter. Institutional investors own 72.76% of the company’s stock.
Key Stories Impacting Harrow
Investors following HROW have been watching these stories:
- Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to a loss of $0.40 from a loss of $0.57, and its Q2 2027 estimate to a loss of $0.10 from a loss of $0.12. The changes suggest some improvement in those periods. Harrow analyst estimate updates
- Neutral Sentiment: Harrow plans to participate in two investor conferences on November 17 and 18, including a presentation at the Jefferies Global Healthcare Conference. The events may give management a chance to discuss the business, but no new financial information was announced. Harrow investor conference announcement
- Negative Sentiment: HC Wainwright cut its FY2027 EPS estimate to $0.50 from $0.88, and its Q4 2027 forecast to $0.92 from $1.07. It also lowered its Q3 2027 estimate to $0.32 from $0.40. These reductions indicate a less optimistic earnings outlook, despite the increases to some other estimates. Harrow analyst estimate updates
Harrow Company Profile
Harrow is a pharmaceutical company focused on developing, acquiring and commercializing treatments for eye conditions. Its portfolio includes prescription ophthalmic medicines used in areas such as dry eye disease, eye inflammation and pain management, as well as products used in eye surgery and clinical settings. The company markets branded products including VEVYE, a treatment for dry eye disease, and IHEEZO, an ophthalmic anesthetic gel. Through its ImprimisRx subsidiary, Harrow also provides compounded medications and related services for ophthalmology practices and patients.
Recommended Stories
- Five stocks we like better than Harrow
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Harrow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow and related companies with MarketBeat.com's FREE daily email newsletter.
